BD's PharMingen buy to help "speed" conversion of research products to clinical use, firm tells analysts.
This article was originally published in The Gray Sheet
Executive Summary
BD/PHARMINGEN COMBINATION TO ACCELERATE CONVERSION OF RESEARCH use reagents to clinical products by capitalizing on Becton Dickinson's expertise in developing products for clinical use and PharMingen's experience in the research market, Deborah Neff, president of BD Immunocytometry Systems, told analysts April 24 in New York City.